Results 21 to 30 of about 104,116 (405)

Postoperative respiratory depression in patients on sublingual buprenorphine: a retrospective cohort study for comparison between postoperative continuation and discontinuation of buprenorphine

JA Clinical Reports, 2022
Background We tested the hypothesis that patients who continued buprenorphine postoperatively experience postoperative respiratory depression less frequently than those who discontinued buprenorphine.
Ryu Komatsu, Michael D. Singleton, Katherin A. Peperzak, Jiang Wu, Emily M. Dinges, Laurent A. Bollag   +5 more
doaj   +1 more source

Survey of Barriers and Facilitators to Prescribing Buprenorphine and Clinician Perceptions on the Drug Addiction Treatment Act of 2000 Waiver

JAMA Network Open, 2022
Key Points Question What are the main barriers and facilitators to obtaining an X-waiver and prescribing buprenorphine in office-based settings after attending an X-waiver training?
H. Lanham, Jennifer Papac, Daniela I. Olmos, Emily L. Heydemann, Nathalia Simonetti, Susanne Schmidt, J. Potter   +6 more
semanticscholar   +1 more source

Buprenorphine initiation strategies for opioid use disorder and pain management: A systematic review

Pharmacotherapy, 2022
Buprenorphine possesses many unique attributes that make it a practical agent for adults and adolescents with opioid use disorder (OUD) and/or acute or chronic pain.
Lauren A Spreen, Emma N Dittmar, Kyle Quirk, Michael A. Smith   +3 more
semanticscholar   +1 more source

Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants

Addiction Science & Clinical Practice, 2022
Background Medications for opioid use disorder (MOUDs), including methadone, buprenorphine, and naltrexone, decrease mortality and morbidity for people with opioid use disorder (OUD).
Barbara Andraka-Christou, Cory Page, Victoria Schoebel, Jessica Buche, Rebecca L. Haffajee   +4 more
doaj   +1 more source

Buprenorphine Waiver Attitudes Among Primary Care Providers

Journal of Primary Care & Community Health, 2022
Background: Despite efforts to improve access to Medications for Opioid Use Disorder (MOUD), such as buprenorphine, the number of opioid overdoses in the United States continues to rise.
Benjamin Lai, Ivana Croghan, Jon O. Ebbert   +2 more
doaj   +1 more source

Buprenorphine and its formulations: a comprehensive review.

Health Psychology Research, 2022
Buprenorphine, a novel long-acting analgesic, was developed with the intention of two purposes: analgesia and opioid use disorder. Regarding its pharmacodynamics, it is a partial agonist at mu receptors, an inverse agonist at kappa receptors, and an ...
Salomon Poliwoda, Nazir Noor, Jack S. Jenkins, Cain W. Stark, Mattie Steib, Jamal Hasoon, G. Varrassi, Ivan Urits, Omar Viswanath, A. Kaye, A. Kaye   +10 more
semanticscholar   +1 more source

Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: A placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients

PLoS ONE, 2022
Background Opioid-induced respiratory depression driven by ligand binding to mu-opioid receptors is a leading cause of opioid-related fatalities. Buprenorphine, a partial agonist, binds with high affinity to mu-opioid receptors but displays partial ...
Laurence M Moss, M. Algera, R. Dobbins, Frank Gray, S. Strafford, Amy Heath, M. van Velzen, J. Heuberger, M. Niesters, E. Olofsen, C. Laffont, A. Dahan, G. Groeneveld   +12 more
semanticscholar   +1 more source

Individual and structural correlates of willingness for intravenous buprenorphine treatment among people who inject sublingual buprenorphine in France

Harm Reduction Journal, 2021
Background Some people do not benefit from oral administration of opioid agonist treatment, and an intravenous (IV) formulation may be more suitable. Our objective was to evaluate the willingness of people who regularly inject sublingual buprenorphine to
Salim Mezaache, Patrizia Carrieri, Laélia Briand-Madrid, Virginie Laporte, Alain Morel, Daniela Rojas Castro, Perrine Roux   +6 more
doaj   +1 more source

High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder

JAMA Network Open, 2021
Key Points Question Is high-dose (>12 mg) buprenorphine induction safe and well tolerated in patients with untreated opioid use disorder who present to the emergency department?
A. Herring, A. Vosooghi, J. Luftig, E. Anderson, Xiwen Zhao, J. Dziura, K. Hawk, R. McCormack, A. Saxon, G. D'Onofrio   +9 more
semanticscholar   +1 more source

Evidence of Buprenorphine-precipitated Withdrawal in Persons Who Use Fentanyl

Journal of addiction medicine, 2021
Objectives Buprenorphine can precipitate withdrawal in opioid-dependent persons with recent fentanyl use. However, the prevalence of this phenomenon is not clinically established.
Neil B. Varshneya, A. Thakrar, J. Hobelmann, K. Dunn, A. Huhn   +4 more
semanticscholar   +1 more source